Quarterly report pursuant to Section 13 or 15(d)

Segments (Details)

v2.4.0.6
Segments (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Dec. 31, 2011
Information regarding our geographic activities          
Operating loss from continuing operations $ (9,369) $ (5,804) $ (27,557) $ (14,714)  
Depreciation and amortization 2,662 1,040 7,447 2,858  
Product sales 11,495 6,760 30,051 22,113  
Total assets 250,022   250,022   229,489
Pharmaceutical [member]
         
Information regarding our geographic activities          
Operating loss from continuing operations (5,593) (262) (17,053) (3,601)  
Depreciation and amortization 2,618 997 7,315 2,731  
Total assets 198,483   198,483   154,437
Corporate [Member]
         
Information regarding our geographic activities          
Operating loss from continuing operations (3,776) (5,542) (10,504) (11,113)  
Depreciation and amortization 44 43 132 127  
Total assets 51,539   51,539   75,048
Discontinued Operations [Member]
         
Information regarding our geographic activities          
Total assets           4
United States [Member]
         
Information regarding our geographic activities          
Product sales              
Chile [Member]
         
Information regarding our geographic activities          
Product sales 6,781 5,356 19,669 17,545  
Spain [Member]
         
Information regarding our geographic activities          
Product sales 1,997    1,997     
Israel [Member]
         
Information regarding our geographic activities          
Product sales 1,516    4,661     
Mexico [Member]
         
Information regarding our geographic activities          
Product sales $ 1,201 $ 1,404 $ 3,724 $ 4,568